ArticleBMC nephrology2026
Clinical outcomes and prognostic factors in lupus nephritis: impact of remission on renal and overall survival in a single-center study.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLupus nephritis (LN) is a severe complication of systemic lupus erythematosus. This study aimed to evaluate clinical outcomes in patients with LN, including progression to chronic kidney disease (CKD), end-stage kidney disease (ESKD), and mortality.
methodsThis retrospective study included all patients diagnosed with LN via kidney biopsy between January 2010 and March 2022. Rates of cumulative renal survival and overall survival, as well as cumulative survival based on the development of ESKD, were compared according to treatment response.
resultsA total of 125 patients with LN were included in the analysis, with a mean follow-up period of 59.9 ± 32.4 months. Overall, 58 patients (46.4%) achieved complete remission, 35 (28%) partial remission, and 32 (25.6%) did not respond to treatment. Baseline clinical characteristics were similar across groups. Patients in complete remission experienced significantly higher rates of cumulative renal and overall survival compared to those with partial or no treatment response (log-rank: P <0.001). Progression to ESKD occurred in 20 patients (16.0%), and 18 (14.4%) died. After multivariable adjustment, low C3 at diagnosis was independently associated with higher odds of treatment non-response (adjusted OR 5.29, 95% CI 1.52-21.3). Achieving complete remission was strongly protective against renal events (doubling of creatinine) (adjusted HR 0.11, 95% CI 0.03-0.39, p < 0.001). Additionally, non-responders were at higher risk of CKD, ESKD, and mortality, with P values of <0.001, 0.005, and 0.014, respectively.
conclusionsThe findings of this study emphasize the importance of early detection, prompt treatment, and vigilant monitoring to optimize patient outcomes. Achieving complete remission is critical for improved renal and overall survival in patients with LN. In particular, low C3 levels at diagnosis was associated with poor treatment response. Future multicenter prospective research is needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.